0
0
covid
A study published in The Lancet Regional Health – Southeast Asia journal compared the effects of different doses of the COVID-19 drug dexamethasone on patients in India and Europe. Researchers, including those from Copenhagen University Hospital – Rigshospitalet, Denmark, assessed the efficacy of a higher dose (12 mg) versus the standard dose (6 mg) of dexamethasone for COVID-19 patients. Surprisingly, the larger dosage didn’t demonstrate the same level of effectiveness for patients in India compared to those in Europe. Survival rates and overall patient recovery after 90 and 180 days were notably less favorable with the higher dose among Indian patients.
The authors cautiously highlighted that while their analysis suggested reduced benefits for Indian patients with the higher dose, the evidence remains somewhat inconclusive, potentially being a chance observation. Safety assessments revealed no significant concerns for Indian patients, but the study underscored how geographical variations and unique challenges in lower-middle-income countries like India might impact the efficacy of treatments.
